Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LBL-054 TDC
- Development stage
- Preclinical
- Lead developer
- LEADS BioLabs
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
LBL-054 TDC is a first-in-class T cell engager drug conjugate (TDC) targeting Cadherin-17 (CDH17) and CD3, developed by Leads Biolabs for the treatment of CDH17-positive gastrointestinal cancers. Utilizing the proprietary TOPiKinectics™ linker-payload platform, the molecule combines the direct cytotoxic killing mechanism of an antibody-drug conjugate (ADC) with the T-cell redirecting activity of a T-cell engager (TCE). CDH17 is highly expressed in gastrointestinal tumors but restricted to tight junctions in normal tissues, providing a favorable therapeutic window. Preclinical studies demonstrate potent anti-tumor activity, bystander killing of CDH17-negative cells, and a lower cytokine release profile compared to conventional TCEs.
02
Targets
CDH17 (Cadherin-17)CD3 (T-cell surface glycoprotein CD3)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on LBL-054 TDC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LBL-054 TDC.